ArticleSurgical case reports2026
Combining Pembrolizumab and Ofatumumab in Triple-Negative Breast Cancer and Multiple Sclerosis: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPembrolizumab has been widely used since its approval as perioperative therapy for triple-negative breast cancer. While the emergence of diverse antibody drugs has expanded therapeutic options in recent years, reports on the combined use of immune-related antibodies in patients with other diseases remain limited. CASE PRESENTATION: A 42-year-old woman presented with a 5-cm mass in her right breast. Needle biopsy confirmed invasive ductal carcinoma (cT2N0M0, cStage IIB, triple-negative breast cancer). Pembrolizumab-based therapy was considered, but the patient was already receiving ofatumumab, an anti-CD20 antibody, for multiple sclerosis (MS). After consultation with a neurologist, she underwent neoadjuvant chemotherapy with paclitaxel, carboplatin, and pembrolizumab, followed by epirubicin, cyclophosphamide, and pembrolizumab. Preoperative imaging indicated a clinical complete response. She underwent right partial mastectomy with sentinel lymph node biopsy, and postoperative pathology confirmed a pathologic complete response. No exacerbation of MS has been observed to date.
conclusionsThis case demonstrates that pembrolizumab can be safely administered for triple-negative breast cancer in a patient receiving ofatumumab for MS, achieving a pathologic complete response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.